Cbl-b-IN-30
Cbl-b-IN-30 is an orally active Casitas B-lineage lymphoma-b (CBLB) inhibitor. Cbl-b-IN-30 specifically binds to CBLB and inhibits its E3 ubiquitin ligase activity with an IC50 of 9.1 nM. Cbl-b-IN-30 can promote IL-2 secretion (EC50 = 187.5 nM) and enhance T cell activation. Cbl-b-IN-30 exerts antitumor activity and can induce immune memory. Cbl-b-IN-30 can be used for the research of colon cancer[1].
Product Specifications
UNSPSC
12352005
Target
E1/E2/E3 Enzyme; Interleukin Related
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease
Field of Research
Cancer
Smiles
C[C@@H]1C[C@@](C2=NN=CN2C)(C3=CC=NC(N4C=NC(C(C(F)(F)F)=CC(CN5CCC[C@@H](C5)C)=C6)=C6C4=O)=C3)C1
Molecular Formula
C29H32F3N7O
Molecular Weight
551.61
References & Citations
[1]Meng F, et al. Discovery and Biological Evaluation of Novel, Potent, and Orally Available CBLB Inhibitors. J Med Chem. 2025;68 (22) :24502-24518.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-2
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
